Overview


According to FutureWise analysis, the whole genome sequencing market in 2025 is US$2.1 billion and is expected to reach US$7.54 billion by 2033 at a CAGR of 17.33%. Market growth is driven by the increasing use of genomic research in precision medicine, oncology, and rare disease diagnosis. Advancements in sequencing technologies, lower costs, and improved data analytics are enabling faster and more accurate genome analyses, broadening clinical and research applications worldwide.

Whole genome sequencing (WGS) is a state-of-the-art genomic technique that enables the determination of the complete DNA sequence of an organism’s genome at once. This comprehensive approach provides in-depth information on all genetic variations—both coding and non-coding—yielding valuable insights into an individual’s genetic profile, potential disease predispositions, and biological processes. In contrast to targeted or exome sequencing, which concentrate on specific genes or regions, WGS examines the entire genome, rendering it the most exhaustive method for genetic analysis.

The WGS process begins by fragmenting DNA, followed by sequencing these fragments using next-generation sequencing (NGS) technologies. The resulting data is then assembled with the help of advanced bioinformatics tools. This sequence data allows researchers and clinicians to pinpoint single nucleotide polymorphisms (SNPs), insertions, deletions, structural variants, and other genomic changes that could impact health and disease risk.

WGS has emerged as a vital tool in fields such as biomedical research, precision medicine, and clinical diagnostics. It is instrumental in uncovering genetic causes of rare diseases, informing cancer treatment strategies, and investigating pathogen evolution and outbreaks. Additionally, it facilitates population genomics studies that enhance our understanding of genetic diversity and disease vulnerability across various demographic groups.

Recent technological advancements in sequencing have considerably lowered costs and reduced turnaround times, making WGS more accessible for both clinical and research purposes. The incorporation of artificial intelligence (AI) and cloud-based bioinformatics platforms has further enhanced data analysis and interpretation, leading to tailored treatment approaches and more precise genetic insights.

As genomic medicine progresses, whole genome sequencing is set to play a fundamental role in the future of precision healthcare. Its capacity to deliver comprehensive genetic information not only improves disease prevention and early diagnosis but also accelerates the development of innovative therapeutics, paving the way for a more personalized and data-driven medical landscape.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Whole Genome Sequencing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Whole Genome Sequencing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California, Inc.
  • BGI
  • QIAGEN
  • Agilent Technologies
  • ProPhase Labs, Inc. (Nebula Genomics)
  • Psomagen
  • Azenta US, Inc. (GENEWIZ)

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type 

  • Large Whole Genome Sequencing
  • Small Whole Genome Sequencing

By Product & Service 

  • Instruments
  • Consumables
  • Services

By Workflow 

  • Pre-sequencing
  • Sequencing
  • Data Analysis

By Application

  • Human Whole Genome Sequencing
  • Plant Whole Genome Sequencing
  • Animal Whole Genome Sequencing
  • Microbial Whole Genome Sequencing

By End Use 

  • Academic & Research Institutes
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Whole Genome Sequencing Market By Type, By Product & Service, By Workflow, By Application, By End Use and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1 Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3.Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Whole Genome Sequencing Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Whole Genome Sequencing Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Whole Genome Sequencing Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Whole Genome Sequencing Market, By Type Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Large Whole Genome Sequencing
        2. Small Whole Genome Sequencing

  • 8.  Whole Genome Sequencing Market, By Product & Service Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Instruments
        2. Consumables
        3. Services

  • 9.  Whole Genome Sequencing Market, By Workflow Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Pre-sequencing
        2. Sequencing
        3. Data Analysis

  • 10.  Whole Genome Sequencing Market, By Application Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Human Whole Genome Sequencing
        2. Plant Whole Genome Sequencing
        3. Animal Whole Genome Sequencing
        4. Microbial Whole Genome Sequencing

  • 11.  Whole Genome Sequencing Market, By End Use Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Academic & Research Institutes
        2. Hospitals & Clinics
        3. Pharmaceutical & Biotechnology Companies
        4. Others

  • 12.  North America Whole Genome Sequencing Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2025-2033

  • 13.  Latin America Whole Genome Sequencing Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2025-2033

  • 14.  Europe Whole Genome Sequencing Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2025-2033

  • 15.  Asia Pacific Whole Genome Sequencing Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2025-2033

  • 16.  Middle East and Africa Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2025-2033

  • 17.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 18.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Drug Types Offered and Financial Layouts)
    •       1. Illumina, Inc.
        1.1. Company Overview
        1.2. Drug Type Portfolio
        1.3. SWOT Analysis
        1.4. Financial Overview
        1.5. Strategic Overview
          2. Thermo Fisher Scientific, Inc.
        2.1. Company Overview
        2.2. Drug Type Portfolio
        2.3. SWOT Analysis
        2.4. Financial Overview
        2.5. Strategic Overview
         3. Oxford Nanopore Technologies
        3.1. Company Overview
        3.2. Drug Type Portfolio
        3.3. SWOT Analysis
        3.4. Financial Overview
        3.5. Strategic Overview
          4. Pacific Biosciences of California, Inc.
        4.1. Company Overview
        4.2. Drug Type Portfolio
        4.3. SWOT Analysis
        4.4. Financial Overview
        4.5. Strategic Overview
          5. BGI
        5.1. Company Overview
        5.2. Drug Type Portfolio
        5.3. SWOT Analysis
        5.4. Financial Overview
        5.5. Strategic Overview
          6. QIAGEN
        6.1. Company Overview
        6.2. Drug Type Portfolio
        6.3. SWOT Analysis
        6.4. Financial Overview
        6.5. Strategic Overview
          7. Agilent Technologies
        7.1. Company Overview
        7.2. Drug Type Portfolio
        7.3. SWOT Analysis
        7.4. Financial Overview
        7.5. Strategic Overview
          8. ProPhase Labs, Inc. (Nebula Genomics)
        8.1. Company Overview
        8.2. Drug Type Portfolio
        8.3. SWOT Analysis
        8.4. Financial Overview
        8.5. Strategic Overview
          9. Psomagen
        9.1. Company Overview
        9.2. Drug Type Portfolio
        9.3. SWOT Analysis
        9.4. Financial Overview
        9.5. Strategic Overview
         10. Azenta US, Inc. (GENEWIZ)
        10.1. Company Overview
        10.2. Drug Type Portfolio
        10.3. SWOT Analysis
        10.4. Financial Overview
        10.5. Strategic Overview

  • 19.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 20.  FutureWise SME Key Takeaway Points for Client
    •    

Partner

Our Clients